The Daily Salvo for February 3, 2013 - "Of Mail and Medicine"
Is the United States Postal Service #39;s decision to discontinue Saturday mail delivery a glimpse of what #39;s to come under Obamacare?
By: dailysalvo
Go here to see the original:
The Daily Salvo for February 3, 2013 - "Of Mail and Medicine" - Video
Frontier Center at the CU School of Dental Medicine
With funding from Delta Dental of Colorado and the Delta Dental of Colorado Foundation, the CU School of Dental Medicine has developed an innovative interprofessional curriculum forging a link between dentistry and medicine for better patient care. CU School of Dental Medicine website: http://www.ucdenver.edu About the School of Dental Medicine: http://www.ucdenver.edu Frontier Center: http://www.ucdenver.edu Video provided by the University of Colorado Denver | Anschutz Medical Campus Visit our YouTube channel: http://www.youtube.com Subscribe to our channel: http://www.youtube.com Visit our website: http://www.ucdenver.edu Visit our newsroom http://www.ucdenver.edu
By: UCDenverVideo
More here:
sports medicine broadcast
By: jeremy Jackson
Read the original post:
TAMPA, Fla., Feb. 12, 2013 /PRNewswire/ -- Sleep doctors around the country have awoken to news of shrinking reimbursement rates for the diagnosis and treatment of sleep related breathing disorders . Sleep Apnea Treatment Centers of America (SATCOA), the pioneer of an office-based, obstructive sleep apnea treatment, offers a business opportunity to help Pulmonologists, ENT's and other sleep medicine focused physicians regain their previously strong streams of revenue while offering a great alternative for treatment and a possible cure to their patients.
In the past, physicians affiliated with sleep clinics were seeing hefty reimbursements from insurance carriers. Medicare spending alone on in clinic-sleep diagnostic studies increased 580% in just nine years' time, to $415 million in 2010, according to a report from the US Office of the Inspector General. This rapid increase proved to be unsustainable.
In the present, Medicare along with other private payers are pushing for less-expensive, at home sleep testing that allows patients to bypass a sleep clinic for their diagnostic studies. This is leaving many sleep doctors without a stream of revenue that was common in the field of sleep medicine. Consequently, New England based sleep clinic, Sleep HealthCenters, filed for bankruptcy and abruptly closed all of its 19 locations in January. This is one of many examples that we are seeing fall victim to this drastic change in reimbursement policy.
SATCOA brings balance back to the field of sleep medicine and allows its physicians to offer a curative, highly-reimbursable treatment option for those patients suffering with sleep apnea while replacing lost revenue from the at-home-sleep study movement. Founder and CEO of Sleep Apnea Treatment Centers of America, Dr. Jeffery Silveira has said, "Sleep physicians will have to hold back on their practice and lab expansion. This will result in a significant cut back on the number of labs across the country. Business as usual will simply not survive without innovation and substantive change."
About Sleep Apnea Treatment Centers of America:
Sleep Apnea Treatment Centers of America proudly serves the sufferers of sleep apnea by offering a curative solution for sleep apnea. By delivering a healthcare franchise model for expansion, we are able to deliver the highest quality healthcare, the most compassionate customer service representatives, and the most sophisticated business model for sleep physicians. Contact the Director of Business Development, David Williams: 855-863-4537 or visit http://www.CureMySleepApnea.com.
See the original post:
Sleep Apnea Treatment Centers of America Offers Rescue to Sleep Medicine Doctors
New Delhi, Feb 13 (IANS) Keeping pace with global developments in drug control, the union health ministry is planning to set up a separate central drug controller for traditional systems of medicine and homeopathy.
"India has a pluralistic healthcare delivery system where the government provides opportunity to every recognised medical system to develop and practice, with a view to provide integrated and holistic healthcare services," Health Minister Ghulam Nabi Azad said Wednesday inaugurating the International Conference on Traditional Medicine for South East Asian Countries here.
"The aim is to provide accessible, affordable, safe and quality healthcare to the people, he said.
Azad said all these medical systems are being utilised in the national healthcare delivery system, each to its potential and availability in different parts of the country.
The process of mainstreaming has been further augmented under the National Rural Health Mission, with co-location of traditional medicine and homeopathy facilities in the primary health network and capacity building of AYUSH practitioners in the national programmes of Reproductive and Child Health, Safe Child Birth, School Health, Anemia control and Malaria eradication, he said.
The minister said AYUSH doctors are now actively involved in national health programmes pertaining to reproductive and child health, school health, anaemia control and immunisation.
The government is planning to set up a separate central drug controller for traditional systems of medicine and homeopathy, senior officials said.
The decision was taken during an conference of traditional medicine in South East Asian countries.
The conference was attended by health ministers of Bangladesh, Bhutan and Nepal. The ministers of indigenous medicine, Sri Lanka and other south east Asian countries, were also present.
India signed a Memorandum of Understanding (MoU) with Bangladesh to cooperate in traditional medicine in the areas of exchange of health professionals, development of human resources and research.
See original here:
India to have separate drug controller for traditional medicine
SAN DIEGO, Feb. 13, 2013 /PRNewswire/ --Shire plc (LSE: SHP, NASDAQ: SHPG), the company's Regenerative Medicine business, its community education program HealTogether, and celebrity chef Charles Mattocks announced today the launch of "The Diabetic You" Mobile Tour. The multi-city tour will stop in Tucson, AZ, Phoenix, AZ, San Diego, CA, Los Angeles and Santa Clara, CA, and feature an array of experts traveling in a brightly-colored recreational vehicle (RV) fully equipped for cooking demonstrations and information stations. "The Diabetic You" tour is designed to provide visitors with easy access to resources to help understand the complications of diabetes.
"Being aware of the complications related to diabetes may help prevent or delay serious issues down the road," said Matthew Pauls, Senior Vice President of Global Commercial Operations for Shire Regenerative Medicine, Inc. "By partnering with Charles Mattocks, we are bringing information and access to experts directly to the people who need it most. Our goal is to increase awareness about the management and treatment of these issues."
Pauls continued, "With the right medical care and healthy life choices, people with diabetes and those touched by diabetes can continue to enjoy life to the fullest."
An avid advocate for patients with diabetes, Mattocks began creating 'The Diabetic You,' a documentary and movement focused on educating and inspiring people around the world. Also known as "The Poor Chef", Mattocks is the author of Eat Cheap but Eat Well and is a frequent speaker on the topic of diabetes.
"After I was diagnosed with Type 2 diabetes, I made it a personal mission to help educate the public about living healthier lives -- starting with healthy eating," said Mattocks. "Together with Shire Regenerative Medicine, I hope to increase awareness not only about the management of diabetes, but stop the ravages of the deadly disease."
"The Diabetic You" Mobile Tour will include a day-long event in each city with fun and interactive activities related to the management and treatment of complications of diabetes, including cooking demonstrations by Mattocks. Leading experts on diabetes will also be onsite to answer questions about potential warning signs for common problems such as high blood pressure, stroke, retinopathy and neuropathy. Additionally, "The Diabetic You" Mobile Tour will be offering visitors a free year-long subscription to Diabetic Living, one of the largest publications in diabetes health.
"The Diabetic You" Mobile Tour's schedule is as follows:
About Charles Mattocks
Since his 2011 diagnosis with type 2 diabetes, "The Poor Chef" Charles Mattocks has become an international advocate for diabetic testing, health, and nutrition. Following early inspiration from his late uncle, Bob Marley, Charles initially pursued an acting career culminating in an Emmy nomination for his performance in "The Summer of Ben Tyler." Following acclaimed acting success, Charles became a regular fixture as a chef on The Today Show, Good Morning America, Martha Stewart, CNN, Dr. Oz, and became the best-selling author of Eat Cheap but Eat Well. Determined to learn, educate, and help others, Charles has since been able to use his celebrity chef status to work with the American Diabetes Association, developing the newest ADA diabetic cookbook and has recently been given the honor of being named a Hero and Blue Circle Champion for the International Diabetes Federation. Ever the champion for diabetic health and education, Charles's passion gave birth to The Diabetic You, a documentary unveiling the influences that have left over 300 Million people worldwide with diabetes.
For further information please contact:
Original post:
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care, today announced that new data on the clinical validation and application of FoundationOne will be presented at the 14th Annual Advances in Genome Biology and Technology (AGBT) Meeting taking place February 20-23, 2013 in Marco Island, Fla.
Phil Stephens, Ph.D., vice president, cancer genomics at Foundation Medicine, has been selected to give the closing address of the conference. In his remarks, Dr. Stephens will present details on the clinical experience derived from the genomic profiling of more than 1,000 tumor samples using FoundationOne.
The schedule for Foundation Medicines presentations is as follows:
Date & Time: Thursday, February 21, 2013 from 1:00 p.m. to 2:30 p.m. EST
Title: Validation of a Million Base-pair Cancer Profiling Assay for Clinical Use
Session: Poster Session
Location: Poster No. 159, Collier Hall
Presenter: Doron Lipson, Ph.D., Foundation Medicine
Date & Time: Friday, February 22, 2013 at 7:50 p.m. EST
Excerpt from:
Seasonal Affective Disorder - Treatment and Research at the UM School of Medicine
Learn how day length and light may affect your mood and learn how research at the University of Maryland School of Medicine is expanding our understanding of Seasonal Affective Disorder (SAD). Teodor T. Postolache, MD, is an associate professor of psychiatry and director of the Mood and Anxiety Program at the University of Maryland School of Medicine. Learn more: medschool.umaryland.edu
By: schoolofmedicine
See the original post:
Seasonal Affective Disorder - Treatment and Research at the UM School of Medicine - Video
Dallas, TX (PRWEB) February 12, 2013
The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multi component, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2008 including financial terms were available including over 550 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
The initial chapters of this report provide an orientation of drug deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerative medicine and stem cells deal making since 2009, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all bio pharma companies.
Go here to read the rest:
On Monday, Pope Benedict XVI became the first pope since the 15th century to announce he would abdicate the papacy. At age 85, he has reached an older age than many of his predecessors who died in the post. Robert Siegel talks with gerontologist Leo Cooney of Yale University about how living longer has influenced our working lives.
Copyright 2013 NPR. For personal, noncommercial use only. See Terms of Use. For other uses, prior permission required.
ROBERT SIEGEL, HOST:
The question that Pope Benedict faced is not one that confronts all of us, should we stick with our job till death do us part. Popes, monarchs and federal judges all face that question, so do some people who are self-employed, and different people answer it differently. The pioneer heart surgeon, Michael DeBakey, famously practiced medicine until the day he died and he died a few months shy of his hundredth birthday.
On the other hand, Queen Beatrix of the Netherlands recently announced that she will abdicate this year at age 75, after 33 years on the throne. Are 21st century 80 and 90-year-olds more fit than their ancestors to remain in positions of authority and responsibility? We're going to talk now with Dr. Leo Cooney, who's a professor of medicine at Yale University where he established the program in geriatrics. Welcome to the program.
LEO COONEY: Thank you.
SIEGEL: Are we indeed living longer, first of all, as a general impression?
COONEY: The striking figure to my mind was at 1950, the male had a five percent of chance, when he reached 50, of living to be 90. In 2003, that chance was 16 percent. Females' chance went from 9.6 to 28 percent. So if you reach the age of 50, you have a much higher chance of making it to 90 than you did 50 years ago.
SIEGEL: Obviously, people do different kinds of jobs. There are forms of physical labor that they're not as much in control of deciding. I'd like to continue being a miner till I'm 85, for example, might be a lot more difficult than I'd like to continue going to the office during that time.
COONEY: Probably the most important thing to remember is that despite the fact that things are better than they were 20 or 30 years ago, that the average 85-year-old in the United States has a high prevalence of disability and also a significant prevalence of dementia.
Continued here:
With Modern Medicine, Aging In A Lifetime Appointment Can Get Complicated
BASKING RIDGE, N.J., Feb. 11, 2013 /PRNewswire/ --Reproductive Medicine Associates of New Jersey (RMANJ) has released in vitro fertilization (IVF) success rates for the year ending December 2011, showing a marked increase in successful pregnancies and live births per cycle initiated. RMANJ, a world-renowned leader in the field of Assisted Reproductive Technology (ART), credits the continued increase in successful pregnancies to their pioneering research in the areas of blastocyst embryo transfer, SelectCCS (Comprehensive Chromosome Screening), trophectoderm biopsy (TE) of embryos for genetic testing, and Single Embryo Transfer (SET).
(Logo: http://photos.prnewswire.com/prnh/20120402/NY80340LOGO )
The 2011 data is based on pregnancy and delivery rates of nearly 2,000 treatment cycles across all age groups. Information is governed by The Society of Assisted Reproductive Technology (SART), the primary organization of professionals dedicated to the practice of Assisted Reproductive Technologies in the United States. RMANJ's full Clinic Summary Report can be viewed at http://www.sart.org.
RMANJ continues to outpace the nation with this latest data showing a live birth rate per cycle initiated of 64.4% in women under 35 years of age. The average number of embryos transferred in this age group was 1.8.
SART Pregnancy Success Rates in Women Under 35 Years
Fresh Embryo Cycles (non-donor eggs)
RMANJ
Nation
Percent of embryos transferred resulting in implantation
62.5%
Read more:
Reproductive Medicine Associates Of New Jersey Releases 2011 IVF Success Rates
Public release date: 11-Feb-2013 [ | E-mail | Share ]
Contact: Natalia Bolotina nboloti1@jhmi.edu 928-266-6318 Johns Hopkins Medicine
World-class standards for clinical outcomes and patient safety are at the core of a landmark affiliation agreement signed today between Johns Hopkins Medicine International (JHI) and Pacfico S.A. Entidad Prestadora de Salud (Pacfico Salud), a Lima, Peru-based subsidiary of Credicorp Ltd. (NYSE: BAP).
The collaboration focuses on a network of Peruvian hospitals, an oncology clinic, clinical and pathology laboratories, and outpatient centers that have recently been acquired by Pacfico Salud.
"This important endeavor is designed to raise the quality of health care services across a vast and committed corps of caregivers," says Steven J. Thompson, chief executive officer of Johns Hopkins Medicine International. "We believe that it will have significant long-term impact on Peruvian health care and are pleased to have the opportunity to collaborate with our colleagues at Pacfico Salud, and to share our innovations and best practices with health care providers in this dynamic country and beyond."
Under the terms of the agreement, which was signed in Baltimore, USA, the two organizations will focus on health system strengthening through patient safety and operational and service efficiencies. Johns Hopkins experts will work together with their Peruvian colleagues in the development of clinical and patient services programs, infection control initiatives, and quality improvement processes. The affiliation will also focus on elevating nursing and introducing innovative care concepts.
The new collaboration also aims to create an enhanced infrastructure for the delivery of patient care. At the same time, it provides a viable platform from which to launch a number of public health-focused programs related to the prevention and early detection of non-communicable diseases.
Accreditation of the network hospitals, outpatient and laboratories will be another primary goal. Currently, there are no Joint Commission International-accredited hospitals in a nation with more than 30 million citizens.
"We are very proud to have signed this agreement. It represents a turning point in the history of Peruvian health care, allowing us to be one of the driving forces of its improvement," says Guillermo Garrido Lecca, general manager of Pacfico Salud. "Through our continued collaboration and knowledge transfer initiatives with a world leader in academic medicine, we aim to become the model for local and international health care institutions."
The affiliation agreement with Johns Hopkins Medicine International is the first of its kind in Peru, one of Latin America's fastest growing economies. It also represents a major step forward for Pacfico Salud as it advances its leadership role in the Peruvian private health care realm.
Originally posted here:
Vultures of Culture - Medicine For The People, On The Verge.
I do not own this song or claim any right to it. Vultures of Culture - Medicine For The People, from the 2009 release, On The Verge. I couldn #39;t find this version on the internet anywhere so I decided to upload it myself. It is the best recorded version in my own humble opinion. Medicine For The People have influenced me so much as a musician and also as a simple human being of this mortal coil. Please enjoy with an open mind and soul. Om Shanti.
By: Tyler Dent
Read the original post:
Vultures of Culture - Medicine For The People, On The Verge. - Video
Laughter Yoga Therapy Sessions - Best Alternate of Medicine
Laughter Yoga is a therapy which help to improve mental as well as physical health. It helps us to make immune system stronger, less respiratory problems, good for heart and blood pressure patient etc. Laughter sessions also helps us to reduce fat, it burns 400 cal per hour approx.
By: Vishwa Prakash
See the article here:
Laughter Yoga Therapy Sessions - Best Alternate of Medicine - Video
SAN FRANCISCO, CA--(Marketwire - Feb 10, 2013) - Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced the publication of research demonstrating the ability of its lead product-candidate, Pexa-Vec (JX-594) to significantly prolong survival in advanced hepatocellular carcinoma (HCC) patients in a randomized dose comparison clinical trial. This research, published in Volume 19, Issue 2 of Nature Medicine, showed a statistically significant dose-dependent overall survival benefit with 14.1 months median overall survival for the high-dose group compared to 6.7 months for the low-dose group (p-value = 0.02). This is the first randomized clinical trial of an oncolytic immunotherapy demonstrating significantly prolonged overall survival.
Pexa-Vec is an oncolytic immunotherapy designed to 1) rapidly de-bulk tumors via tumor cell lysis, 2) activate an antivascular effect with rapid tumor vascular knockout, and 3) induce a durable immune response against tumors. Pexa-Vec was engineered from vaccinia, which has been used for decades as a vaccine in healthy individuals. Pexa-Vec has been safely administered to over 200 patients and is currently in Phase 2b clinical development for the treatment of advanced HCC and is also being evaluated in other solid tumors.
"The treatment options for advanced HCC are limited, with few promising agents currently in development. This Nature Medicine publication highlights the unique possibility of a meaningful survival benefit combined with short-term, transient and manageable side effects," said Tony Reid, M.D., Ph.D., professor of Medicine at University of California, San Diego and co-lead author of the paper. "The findings also showed Pexa-Vec's ability to induce anti-tumor immunity and reduce blood flow to tumors which supports Pexa-Vec's multi-pronged approach to attacking cancer."
The data presented in the Nature Medicine publication showed that Pexa-Vec had clear local anti-cancer response at both the low and high doses. Thirty subjects were randomized into the low and high dose groups and received three Pexa-Vec treatments over the course of four weeks. The results demonstrated that Pexa-Vec treatment at both doses resulted in a reduction in tumor size and decreased blood flow in tumors. The data further demonstrates that Pexa-Vec treatment induced an immune response against the tumor, evidenced by antibody-mediated tumor cell toxicity. Pexa-Vec was well-tolerated at both high and low doses with the most frequent adverse events consisting of fever lasting less than 24 hours.
"This Nature Medicine publication validates our clinical data and the scientific rationale for our approach to treating cancer with oncolytic immunotherapy as well as the continued development of Pexa-Vec for the treatment of HCC and other solid tumors," said Laurent Fischer, M.D., president and chief executive officer of Jennerex. "The opportunity to rapidly de-bulk tumors and provide a long-term immune effect is a significant advance in the treatment of HCC. We are currently enrolling patients in multiple mid and late-stage trials with Pexa-Vec with the goal of bringing this groundbreaking therapy to market."
Pexa-Vec Clinical Development Program and SOLVE PlatformPexa-Vec (JX-594) is currently being evaluated in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. It is also being tested in HCC patients in combination with sorafenib. In addition, Pexa-Vec is being evaluated in a Phase 1-2 clinical trial in patients with treatment-refractory colorectal cancer as monotherapy and in combination with irinotecan.
Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that Pexa-Vec, delivered either directly into tumors or intravenously, induces tumor shrinkage and/or necrosis and is well-tolerated (over 200 patients treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. Pexa-Vec has had a predictable and manageable safety profile to date which includes flu-like symptoms that resolve in 24 to 48 hours.
Pexa-Vec is the lead product candidate from Jennerex' SOLVEplatform, a groundbreaking approach offering new therapeutic options for patients with life-threatening cancers. SOLVE builds on the natural attributes of vaccinia viruses to engineer highly targeted, oncolytic immunotherapies for cancer with minimal side effects.
About Jennerex's Regional Partners for Pexa-VecTransgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, holds an exclusive license to develop and commercialize Pexa-Vec in Europe and neighboring countries. Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, holds an exclusive license to develop and commercialize Pexa-Vec in South Korea, and Lee's Pharmaceutical Ltd. holds an exclusive license to develop and commercialize Pexa-Vec in China.
Transgene, a member of the Institut Mrieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. Transgene has four compounds in phase 2 clinical development: TG4010 and Pexa-Vec (TG6006) having already completed initial phase 2 trials, TG4001 and TG4040. Transgene has concluded three strategic agreements for the development of its immunotherapy products: an option agreement with Novartis for the development of TG4010 to treat various cancers; an in-licensing agreement with US-based Jennerex, Inc. to develop and market Pexa-Vec (TG6006), an oncolytic virus, and with the EORTC for the development of TG4001 to treat HPV induced head and neck cancers. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available at http://www.transgene.fr.
See the article here:
The Heart-Mantra Of Medicine Master Buddha (Buddhist Chants: Music For Contemplation Reflection)
If you like what you see and here please leave a comment or press the like button. Also please spread good things to your friends. Thanks.
By: #3605; #3632; #3621; #3629; #3609; #3607; #3637; #3623; #3637; #3605; #3632; #3621; #3629; #3609; #3585; #3636; #3609; #3607; #3637; #3623; #3637;
Read more here:
The Heart-Mantra Of Medicine Master Buddha (Buddhist Chants: Music For Contemplation
Medicine Wheel @ Al #39;s Whisky Bar - Wild Horses
Medicine Wheel Charley Orlando Mike Vincitore Aaron Fried Marc Stell
By: Patrick Corbett
See original here:
Elvis Costello plays "Bad Medicine" for Timothy White
Rare - Elvis Costello plays "Bad Medicine" for Timothy White
By: reedrow
Read the original post:
Elvis Costello plays "Bad Medicine" for Timothy White - Video
Black Medicine The Zone Coffee House Concert 1995.mp4
The Band " Black Medicine " Concert at The Zone Coffee House 1995
By: cchaushoff
Go here to read the rest:
Black Medicine The Zone Coffee House Concert 1995.mp4 - Video
Multispecialty center slated to open March 1 to deliver primary care and subspecialty clinical care services
CHICAGO, Feb. 8, 2013 /PRNewswire-USNewswire/ --Northwestern Medicine today announced that on March 1 it will open a new Outpatient Center at 2701 Patriot Boulevard in Glenview, Illinois. At this new center, 20-30 physicians will offer patients a wide range of primary care and specialty clinical services.
"We know that many of our patients travel from far-reaching suburbs to receive care at Northwestern," said Norman Botsford, chief operating officer of Northwestern Medical Faculty Foundation (NMFF). "Expanding our outpatient services into the communities where patients live and work alleviates the need to travel into Chicago to receive the Northwestern care they've come to trust and value. And most importantly if inpatient care is ever needed, these locations afford seamless transition into Northwestern Memorial Hospital and Northwestern Lake Forest Hospital."
The new Outpatient Center is part of previously announced plans to expand access to Northwestern's quality clinical care in the northern suburbs. The Glenview site is one of seven new Northwestern Medicine clinics, five of which have already opened in Chicago's Lakeview neighborhood, Evanston, Libertyville, Grayslake and Highland Park, Illinois. Northwestern Medicine will open the seventh clinical site in north suburban Deerfield, Illinois this spring.
Primary care services to be offered at the Glenview Outpatient Center include internal medicine and pediatrics. Specialty services will include cardiology, dermatology, gastroenterology, general surgery, neurology, oncology, ophthalmology, optometry, orthopaedics, otolaryngology, sports medicine and urology. Laboratory and X-ray services will be offered immediately with advanced imaging serviceslike MRI screens and CT scanningto be offered by summer 2013.
A major clinical offering of this site will be Northwestern Immediate Care, which opens late spring. Immediate Care requires no appointment and accepts walk-in, or ambulatory, minor emergencies. It will address emergent ailments like flu and fevers, lacerations, strains and sprains and more. Major injuries and traumas should still be directed to full-service emergency rooms.
"We are excited to expand access to Northwestern Medicine care in surrounding suburban communities like Glenview," said Daniel Derman, MD, vice president, Northwestern Memorial, and president, Northwestern Memorial Physician's Group (NMPG). "This new operational model reflects the collective strengths of Northwestern Medicine. Systematically, primary care can work as a portal into specialty care services where needed, all while offering Immediate Care to address minor emergenciesand, the best part for patients is that it's close to home."
Once fully realized, this expansion will have brought about 100 new primary care physicians and more than 40 specialists from NMPG and NMFF into these suburban locations. All of the physicians will have faculty appointments at Northwestern University Feinberg School of Medicine.
At the Glenview Outpatient Center, primary and specialty care, and laboratories and imaging will operate Monday through Friday from 8 am to 6 pm. Once open, Immediate Care will operate year-round from 8 am to 8 pm. For more information please visit us online at http://www.northwesternmedicine.org/glenview or call us at (847) 724- GLEN [4536].
About Northwestern Medicine
See the rest here:
Northwestern Medicine® Announces New Glenview Outpatient Center